Cvt19 Inhibitors
Cvt19 inhibitors can, either directly or indirectly, impact the function or expression of the ATG19/Cvt19 protein. Central to the realm of autophagy, these inhibitors typically exert their effects by meddling with the intricate autophagic machinery, of which ATG19 plays a pivotal role.
Most inhibitors, such as Wortmannin and 3-Methyladenine, target PI3K, a critical kinase involved in the initiation of autophagy. Bafilomycin A1 and Concanamycin A, on the other hand, focus on the latter stages of the autophagy process, particularly the fusion of autophagosomes with lysosomes. This blockage results in a buildup of autophagosomes, thus stunting autophagic flux. Chloroquine follows a similar mechanism by impairing lysosomal acidification. The microtubule-disrupting agent, Vinblastine, impedes the transport of autophagosomes, while agents like Niclosamide disrupt ATP production, affecting cellular energy homeostasis and indirectly autophagy.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, a kinase involved in autophagosome formation. By doing so, it can limit ATG19's opportunity to bind and facilitate autophagosome-vesicle fusion. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
Inhibits class III PI3K, preventing early stages of autophagosome formation. This can reduce ATG19's functional role in binding autophagic cargoes. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
This compound inhibits vacuolar ATPase, preventing autophagosome-lysosome fusion. As a result, the role of ATG19 in guiding cargoes to the vacuole is compromised. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Targets ubiquitin-specific peptidases, leading to decreased autophagy. This can potentially limit the pool of autophagic cargoes that ATG19 binds. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
An inhibitor of PI3K, it halts autophagosome formation. This can reduce the instances where ATG19 binds and shuttles autophagic cargoes. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $115.00 $1056.00 | 7 | |
By inhibiting Src kinase, it may affect various stages of autophagy, potentially disrupting the normal binding activities of ATG19. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
This dynamin inhibitor affects endocytosis and some autophagy-related processes. This may limit the substrate availability for ATG19. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
By disrupting microtubules, it hinders autophagosome transport, thus potentially preventing ATG19 from executing its cargo delivery function. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Affects mitochondrial respiratory chain and ATP production. The cellular energy imbalance may indirectly impact the functioning or binding dynamics of ATG19. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Induces ER stress and affects calcium homeostasis. This can potentially disrupt the normal cellular context in which ATG19 operates. | ||||||